Figure 3.
RANKL treatment does not enhance SMC calcification. Differentiated BMDMs do not for osteoclasts in response to RANKL. (A) SMCs were treated with CM or HPM in the presence of 100ng/ml of RANKL or vehicle. (B) and (C) TRAP staining. (B) BMDM differentiated for 7 days in M-CSF (20ng/ml) and ten treated for 7 more days with M-CSF (20ng/ml) and RANKL (50ng/ml). (C) RAW264.7 treated for 3 days with RANKL (50 ng/ml) form TRAP positive multinucleated cells.